Ignite Creation Date:
2024-05-06 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05051449
Status:
TERMINATED
Last Update Posted:
2024-03-07
First Post:
2021-09-10
Brief Title:
Ketamine for OUD and Comorbid Depression OUDCD
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Increasing Retention in Methadone Maintenance Treatment Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression OUDCD
Status:
TERMINATED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study funds were exhausted
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Methadone is a first-line evidence-based treatment for opioid use disorder OUD Unfortunately retention and adherence in methadone treatment is a major challenge OUD patients frequently present with co-morbid depression OUDCD a risk factor for poor OUD treatment outcomes overdose and suicide The last two decades have seen an exciting and transformational development in the treatment of depression - ketamine As a safe rapid-acting anti-depressant deliverable within the context of methadone maintenance treatment ketamine could feasibly change the landscape of treatment for OUD patients with comorbid depression This proposal seeks to evaluate implementation outcomes feasibility and patient acceptance as well as preliminary efficacy of ketamine on methadone treatment outcomes for OUD patients n6 with comorbid depression and depressive symptoms presenting for methadone treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None